Form D · Pharmaceuticals
Crosslink Therapeutics Inc.
Boston, MA · CIK 0002067583
Offering snapshot reported Oct 20, 2026 · SEC filing
- Reported sold
- $5.5M Offering amount: $5.5M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 8, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 20, 2026 | Initial | $5,500,000 | No comparison | 8 | SEC filing |
| May 15, 2025 | Initial | $4,250,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-601863
Source: Form D, filed Oct 20, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rodolfo Chaparro | Director |
| David Fallace | Director |
| Cameron Gallagher | Director |
| Andrew King | Director |
| Ronald D. Seidel, Iii | Director, Executive |
| Lou Tartaglia | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
349 351 Newbury Street
Boston, MA, 02115
Boston, MA, 02115